ATX-559
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ATX-559, covering 2026-02-24 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers [Phase 1]